The medtech industry is brimming with innovation, but its most vital resource remains its people. During a panel discussion at LSI USA ’24, experts tackled one of the most pressing issues facing organizations today: addressing human capital challenges while fostering growth and sustainability. Featuring insights from David Kereiakes of Windham Venture Partners, Charles Rohaut, Alex Bennett, and Jeff Mollica of ZRG Partners, alongside Evan Luxon of Centese, the session explored how companies can attract, retain, and develop top talent in an increasingly competitive landscape.
The journey to medtech success is often paved with critical decisions about funding and partnerships. For many entrepreneurs, navigating the complex world of medtech venture capital can be daunting. During a panel at LSI USA ‘24, industry leaders Dennis McWilliams of Santé Ventures, Thom Rasche of Earlybird Venture Capital, Amir Soltanianzadeh of Solardis Health Ventures, Owen Willis of Opal Ventures, and life science investor Nancy Hong pulled back the curtain on how VCs operate, their investment philosophies, and the dynamics that shape funding in the medtech space.
Success in medtech innovation requires more than groundbreaking technology. During a panel at LSI USA ‘24, Ivanny Franklin of NAMSA emphasized the pivotal role of clinical and regulatory strategies in shaping investment decisions and driving long-term outcomes. Joined by distinguished panelists—Auriel August of Santé Ventures, Edwin Lindsay of Compliance Solutions Life Sciences, Nir Goldenberg of Mayo Clinic Ventures, and Adam Saltman of NAMSA—Franklin explored how regulatory rigor and clinical diligence intersect with investment value.
